Furthermore, flow cytometry analysis of intratumoral immune cell frequencies indicated that the increase in CD4+ and CD8+ T cells in dual-ICI-treated tumors was counteracted by the anti-Ly6G antibody and that the frequency of intratumoral cytotoxic CD8+ T cells (CD8+granzyme B+ cell fraction) was significantly reduced in a neutrophil-lacking tumor microenvironment (Fig. 4c). The gene discussed is CD8A; the disease is neoplasm.